Cinqair (reslizumab) IV — Prior Authorization Coverage Criteria
Customize your policy alerts
Sign up for all AvMed policy alerts
Know when AvMed releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria and administrative requirements for AvMed coverage of Cinqair (reslizumab) intravenous therapy for members, including initial and reauthorization clinical criteria and documentation requirements; applies to providers requesting medical benefit coverage for the drug.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.